BioSolutions GmbH

Saale, Germany

BioSolutions GmbH

Saale, Germany
Time filter
Source Type

News Article | December 19, 2016

RICHMOND, Va.--(BUSINESS WIRE)--Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected five new members to their Board of Directors for a term of three years. The election took place on December 8, 2016 at the Virginia Bio Annual Membership meeting in Richmond, Virginia. The newly elected directors are: Rony Thomas, President & CEO, LifeNet Health; Thomas Frantz, Chairman Emeritus, Williams Mullen; Julie Idelkope, Vice President, US Government Relations, Pfizer; Amrie Grammer, COO & CSO, Ampel BioSolutions; Ross Dunlap, President & CEO, Ceres Nanosciences; and Mickey Kim, Director, Biotech Partnering & Strategy, MedImmune. “I’m pleased to join the VA Bio board and am excited to bring my experience as a biotech entrepreneur to help drive the growth and success of Virginia’s life sciences industry,” said new board member, Ross Dunlap. Members also elected Brian Pollok, CEO, Neoantigenics, Cynthia Rancourt, CEO, Polymer Solutions and Carl Sahi, CEO, Engineered Biopharmaceuticals, Inc. to serve a second three-year term on the Board of Directors. Chairman of the board, Crystal Icenhour said, "I am looking forward to working with our new board members. They each bring a unique set of skills that will further enrich our board." Rony Thomas serves as the President and CEO of LifeNet Health. LifeNet Health Inc., based in Virginia Beach, is one of the world’s largest Life Sciences not-for-profit organizations specializing in organ, tissue and cell procurement and the utilization of tissue for biomedical applications in a variety of surgical disciplines. Prior to joining LifeNet Health, Mr. Thomas served as CEO and held other executive leadership positions at USA Instruments, a General Electric company. Mr. Thomas has over 20 years of experience in the medical device and Tissue Engineering industries, working in entrepreneurial and major corporate settings. Thomas Frantz currently serves as Chairman Emeritus of the Board for Williams Mullen. Drawing on his tax background, he also maintains a robust corporate legal practice as a Partner representing multi-national corporations, handling major mergers and acquisitions, and advising corporations on a variety of legal matters. Tom previously served as President and Chief Executive Officer of the firm from 2010 to 2015. Before joining the firm, Tom was an original principal with Clark & Stant, which merged with Williams Mullen in 1999. He became General Counsel to Tidewater Health Care, Inc., the parent company of Virginia Beach General Hospital, in 1989. He currently serves as Outside Corporate Counsel to Armada Hoffler Properties, Inc., a NYSE REIT. Along with Rony Thomas he Co-chaired the Mayor of Virginia Beach’s Bioscience Task Force, which was comprised of 20 university, healthcare and bioscience executives from Charlottesville to the Oceanfront, which developed a regional bioscience plan from UVA to the Oceanfront, with multiple hubs. Julie Idelkope is the Vice President for US State Government Relations for Pfizer Inc. She has over 20 years of experience in corporate government affairs and as a state and local public official. Julie developed and directed the government affairs strategy for a number of America’s leading corporations including Burger King Corporation, the Minnesota Twins Baseball Club, Wal-Mart Stores and Northwest Airlines. Julie served as the Deputy Commissioner of Trade, Tourism and Economic Development during the administration of Governor Jesse Ventura and as the Deputy Mayor to Minneapolis Mayor Sharon Sayles Belton. Dr. Amrie Grammer is the co-founder, COO and CSO of AMPEL BioSolutions, LLC located in Charlottesville, Virginia. AMPEL uses cutting-edge data science techniques to identify “druggable” pathways in autoimmune diseases and analyze them with state-of-the-art clinical trials. Specifically, AMPEL specializes in translational and personalized medicine including drug and target identification, protocol design and management, biomarker identification, and bioinformatic analysis. Amrie is a PhD Translational Immunologist specializing in human Autoimmune Diseases and headed up the B Cell Biology Group in the Autoimmunity Branch of NIAMS at the NIH before heading to Charlottesville to found AMPEL. She has also worked as an independent research consultant specializing in clinical trials, biomarkers, cell-cell interactions & the biochemistry of signaling cascades with expertise in primary lymphocyte biology, flow cytometry, and bioinformatics of gene expression & proteomics. Ross Dunlap is the CEO and a co-founder of Ceres Nanosciences. In the role of CEO, Ross is responsible for strategic planning, technology development and product commercialization; financial management and capital fundraising; and business development and industry partnerships. Ross has led Ceres since its inception during which time he has raised over $8M in Angel and grant funding, overseen the build out of a highly effective and efficient business infrastructure and team, and established multiple high-profile partnerships with industry and academic leaders. Currently, Ross is directing the clinical development, validation, and market launch of a novel Lyme Antigen Test that will provide the most sensitive and accurate detection of Lyme disease. Ross has over 20 years of experience working in operational and strategic business development. He began his career with Arthur Andersen's Business Consulting practice, working with start-up technology companies to establish and grow critical business operations and deliver services and technologies to new markets. Following this, Ross spent five years with Washington Consulting, where he helped build the firm from the ground up into a successful and profitable enterprise that ultimately was acquired by a large defense contractor. Dr. Mickey Kim is the Director of Partnering and Strategy and Head of Out-licensing / Spin outs at MedImmune, the biologics research and development arm of AstraZeneca. Dr. Kim joined MedImmune in 2013 and assumed his current role in 2015, in which he established and leads the out-licensing and spin out group for the company. During the past three years, Dr. Kim and his team have completed numerous business development deals, out-licensing transactions, spin outs and ecosystem collaborations. He has led efforts to grow the bioscience ecosystem in MedImmune’s key locations, including Maryland and the UK. Prior to MedImmune, Dr. Kim was a venture capital investor with Canaan Partners and BioVentures Investors. Earlier in his career, he was an entrepreneur, co-founding a technology incubator and investment fund in Asia, and a strategy consultant with McKinsey & Company and CSC Healthcare. He holds a Doctor of Medicine from the Feinberg School of Medicine and Masters of Business Administration from the Kellogg School of Management, Northwestern University. You can view the complete list of Virginia Bio board members at Virginia Bio is the premier statewide non-profit trade association for life sciences, promoting the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. Virginia Bio is an advocate for innovation and entrepreneurship, and for the biopharmaceutical, and other health technology industries among federal, state and local policy-makers. Virginia Bio is the official state affiliate of the Biotechnology Industry Organization (BIO), AdvaMed and the Medical Device Manufacturers Association (MDMA) and also collaborates closely with the Pharmaceutical Research and Manufacturers of America (PhRMA). To learn more, visit or Follow Virginia Bio on Twitter at @VABio.

News Article | March 1, 2017

Phenomenex’s two additions to its BioSolutions portfolio offer high-efficiency reversed-phase characterization of synthetic DNA and RNA. The Clarity Oligo-XT C18 columns feature novel and robust core-shell media and increased sensitivity that improves quantitation by mass spectrometry. The core-shell particles deliver the separation power necessary to accurately resolve closely related synthetic oligonucleotide sequences. The columns are available in directly scalable 1.7, 2.6 and 5µm particle sizes that enable easy method transfer between analytical HPLC/UHPLC instrumentation and preparative purifications systems. The Clarity Oligo-SAX columns feature an entirely new, rugged non-porous particle that retains synthetic oligonucleotides through strong ion exchange mechanisms, adding a robust strong anion exchanger choice with improved column lifetimes to the Clarity family. These quaternary amine functionalized, nonporous particles are engineered for performance at high pH (2.5 to 12.5) and temperatures up to 85C and are provided in 5µm particle size for analytical characterization. Phenomenex, Inc., 310-212-0555

Lechner E.,Conventionne Avec Luniversite Of Strasbourg | Leonhardt N.,CEA Cadarache Center | Eisler H.,Conventionne Avec Luniversite Of Strasbourg | Eisler H.,BioSolutions GmbH | And 5 more authors.
Developmental Cell | Year: 2011

Being sessile organisms, plants need rapid and finely tuned signaling pathways to adapt their growth and survival over their immediate and often adverse environment. Abscisic acid (ABA) is a plant hormone crucial for both biotic and abiotic stress responses. In this study, we highlight a function of six Arabidopsis MATH-BTB proteins in ABA signaling. MATH-BTB proteins act as substrate-binding adaptors for the Cullin3-based ubiquitin E3 ligase. Our genetic and biochemical experiments demonstrate that the MATH-BTB proteins directly interact with and target for proteasomal degradation the class I homeobox-leucine zipper (HD-ZIP) transcription factor ATHB6, which was previously identified as a negative regulator of ABA responses. Reducing CUL3 BPM function leads to higher ATHB6 protein accumulation, reducing plant growth and fertility, and affects stomatal behavior and responses to ABA. We further demonstrate that ABA negatively regulates ATHB6 protein turnover, a situation reminiscent to ABI5, another transcription factor involved in ABA signaling. © 2011 Elsevier Inc.

Kommera H.,Martin Luther University of Halle Wittenberg | Kaluderovic G.N.,Martin Luther University of Halle Wittenberg | Kaluderovic G.N.,University of Belgrade | Kalbitz J.,BioSolutions GmbH | And 2 more authors.
European Journal of Medicinal Chemistry | Year: 2010

In the present investigations five new derivatives of betulinic and betulonic acid were synthesized and the effect of this structural variations on anticancer activity was studied and discussed. The anti-proliferative activity of betulinic and betulonic acid derivatives was studied against eight tumor cell lines of different histogenic origin. The derivatives exerted a dose dependent antiproliferative action at micromolar concentrations toward target tumor cell lines. The apoptotic mode of cell death on colon cancer cell line HT-29 was induced by the most active compounds 5,2-amino-3-hydroxy-2-(hydroxy-methyl) propyl (3-O-acetyl)betulinate,and 9,2-amino-3-hydroxy-2-(hydroxymethyl)propyl betulonate. Treatment of HT-29 cells with 5 and 9 induced apoptosis,as observed by dye exclusion test (trypan blue) and by the appearance of a typical ladder pattern in the DNA fragmentation assay and FITC annexin V assay. Cell cycle perturbations caused by compound 5 are also presented. © 2010 Elsevier Masson SAS. All rights reserved.

Kommera H.,Martin Luther University of Halle Wittenberg | Kaluderovic G.N.,Martin Luther University of Halle Wittenberg | Kaluderovic G.N.,University of Belgrade | Kalbitz J.,BioSolutions GmbH | Paschke R.,Martin Luther University of Halle Wittenberg
Investigational New Drugs | Year: 2011

In the present investigation the antiproliferative activity of thirteen derivatives of betulinic acid and betulin was tested against five different tumor cell lines. The toxicity against normal human fibroblasts (WWO70327) and the mode of cell death on HT-29 (colon cancer) as well as caspase activity induced by the most active compounds, 9 (3-O-chloroacetylbetulinic acid) and 15 (28-O-chloroacetylbetulin) were determined. Investigated derivatives exerted a dose dependent antiproliferative action at micromolar concentrations toward target tumor cell lines. Treatment of HT-29 cells for 24 h with 9 and 15 induced apoptosis, as observed by dye exclusion test (trypan blue) and confirmed by the appearance of a typical ladder pattern in the DNA fragmentation assay. © Springer Science+Business Media, LLC 2009.

Kaluderovic G.N.,Martin Luther University of Halle Wittenberg | Kaluderovic G.N.,University of Belgrade | Tayurskaya V.,BioSolutions GmbH | Paschke R.,Martin Luther University of Halle Wittenberg | And 3 more authors.
Applied Organometallic Chemistry | Year: 2010

The carboxylate compounds [Ti(η5-C5H 5)(η5-C5H4{CMe 2(CH2CH2CH=CH2)})(O 2CCH2SXyl)2] (2; Xyl = 3,5-Me2C 6H3) and [Ti(η5-C5H 5)(η5-C5H4{CMe 2(CH2CH2CH=CH2)})(O 2CCH2SMesl)2] (3; Mes 1 = 2,4,6-Me 3C6H2) were synthesized by the reaction of [Ti(η5-C5H5)(η5-C 5H4{CMe2(CH2CH2CH CH 2)})Cl2] (1) with 2 equivalents of xylylthioacetic acid or mesitylthioacetic acid, respectively. Compounds 2 and 3 were characterized by spectroscopicmethods. The cytotoxic activity of 1-3 was tested against human tumor cell lines from four different histogenic origins - 8505C (anaplastic thyroid cancer), DLD-1 (colon cancer) and the cisplatin sensitive A253 (head and neck cancer) and A549 (lung carcinoma) - and comparedwith those of the reference complex [Ti(η5-C5H5) 2Cl2] (R1) and cisplatin. Surprisingly, the cytotoxic activities of the carboxylate derivatives were lower than those of their corresponding dichloride analogue (1). However, complexes 1-3 were more active than titanocene dichloride against all the studied cells with the exception of complex 2 against A253 and A549 cell lines. DNA-interaction tests were also carried out. Solutions of all the studied complexeswere treated with different concentrations of fish sperm DNA, observing modifications of the UV spectra with intrinsic binding constants of 2.99 × 105, 2.45 × 105, and 2.35 × 105 M-1 for 1-3. Structural studies based on density functional theory calculations of 2 and 3 were also carried out. Copyright © 2010 John Wiley & Sons, Ltd.

Csuk R.,Martin Luther University of Halle Wittenberg | Barthel A.,Martin Luther University of Halle Wittenberg | Kluge R.,Martin Luther University of Halle Wittenberg | Strohl D.,Martin Luther University of Halle Wittenberg | And 2 more authors.
Bioorganic and Medicinal Chemistry | Year: 2010

The reaction of betulinic aldehydes with various carbon nucleophiles gave a series of new betulin derivatives, among them epoxides, glycidic derivatives and β-hydroxy carbonyl compounds. Subsequent transformations of the β-hydroxy carbonyls lead to 1,3-diketo- and α,β-unsaturated betulin derivatives. These compounds were assayed for cytotoxicity using 15 human cancer cell lines and a colorimetric SRB-assay. Several compounds revealed significant antitumour activity. © 2009 Elsevier Ltd. All rights reserved.

Behr S.,Ludwig Maximilians University of Munich | Fried L.,Ludwig Maximilians University of Munich | Fried L.,BioSolutions GmbH | Jung K.,Ludwig Maximilians University of Munich
Journal of Bacteriology | Year: 2014

When carbon sources become limiting for growth, bacteriamust choose which of the remaining nutrients should be used first. We have identified a nutrient-sensing signaling network in Escherichia coli that is activated at the transition to stationary phase. The network is composed of the two histidine kinase/response regulator systems YehU/YehT and YpdA/YpdB and their target proteins, YjiY and YhjX (both of which aremembrane-integrated transporters). The peptide/amino acid-responsive YehU/YehT systemwas found to have a negative effect on expression of the target gene, yhjX, of the pyruvate-responsive YpdA/YpdB system, while the YpdA/YpdB systemstimulated expression of yjiY, the target of the YehU/YehT system. These effects were confirmed in mutants lacking any of the genes for the three primary components of either system. Furthermore, an in vivo interaction assay based on bacterial adenylate cyclase detected heteromeric interactions between themembrane-bound components of the two systems, specifically, between the two histidine kinases and the two transporters, which is compatible with the formation of a larger signaling unit. Finally, the carbon storage regulator A (CsrA) was shown to be involved in posttranscriptional regulation of both yjiY and yhjX. © 2014, American Society for Microbiology.

Kommera H.,Martin Luther University of Halle Wittenberg | Kaluderovic G.N.,Martin Luther University of Halle Wittenberg | Dittrich S.,Martin Luther University of Halle Wittenberg | Kalbitz J.,BioSolutions GmbH | And 3 more authors.
Bioorganic and Medicinal Chemistry Letters | Year: 2010

Synthesis and antiproliferative activity of eight new derivatives of betulinic acid (1) and betulin (2) are described. The compounds were tested against fifteen tumor cell lines. The toxicity against normal human fibroblasts and the mode of cell death on lung cancer cell line induced by the most active compounds 9 (bis(ethylcarbamate)betulin) and 11 (3-O-ethylcarbamate of 28-O-acetylbetulin) was investigated. Caspase 3 activity on lung cancer cell line (A549) was determined for 1, 5 (3-O-ethylcarbamate of betulinic acid), 9 and 11. All derivatives exerted a dose dependent antiproliferative action at micromolar concentrations toward target tumor cell lines. Treatment of lung cancer cells for 24 h with 9 and 11 induced apoptosis, as observed by the appearance of a typical ladder pattern in the DNA fragmentation assay. © 2010 Elsevier Ltd. All rights reserved.

Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH-2007-2.4.2-5 | Award Amount: 3.57M | Year: 2009

A key problem in repair and functional regeneration following myocardial infarction is the inability of heart muscle tissue to regenerate itself and appropriate vascularization under conditions of increased strain caused by the reduced contractibility of the damaged heart. This frequently leads to continuous loss of functional cells, further increase of the infarct area and finally complete loss of heart function. We propose to explore possibilities for cell therapy using different procedures and sources of stem and progenitor cells. First, we will investigate factors stimulatory for stem/progenitor cell release from the bone marrow, their recruitment to the heart and the activation of resident heart stem cells. Second, we will evaluate adoptive transfer of stem/progenitor cells of different sources, from bone marrow, adult and cord blood, adipose tissue and heart tissue itself. The use of ex vivo cultured and differentiated cells including embryonic stem cells will be tested. Third, we will test genetic modification of these cells for improved differentiation, homing and tissue repair. Fourth, we will use a unique artificial scaffold material as a slow release device for factors and as a structural support material for providing the different cell preparations to the damaged areas. This scaffold will aso be used for tissue engineering in vitro followed by insertion of artficial tissue onto the infarct area. This project of high clinical importance is designed to further support the research and development needs of two SMEs, one is determined to become a supplier of growth factor cocktails for clinical stem cell culture, a second is based on the generation and supply of stem cells for clinical use. It will evaluate whether induction of repair by factors, adoptive transfer of stem/progenitor cells or engineered tissue has benefit for heart regeneration and has potential to become a future clinical standard therapy.

Loading BioSolutions GmbH collaborators
Loading BioSolutions GmbH collaborators